R Abele

463 total citations
23 papers, 369 citations indexed

About

R Abele is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, R Abele has authored 23 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in R Abele's work include Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (3 papers) and Multiple Myeloma Research and Treatments (2 papers). R Abele is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (3 papers) and Multiple Myeloma Research and Treatments (2 papers). R Abele collaborates with scholars based in Switzerland, Belgium and United States. R Abele's co-authors include M. Clavel, Herbert M. Pinedo, M. van Glabbeke, J. Renard, Marcel Rozencweig, F. Cavalli, P. Alberto, P. Dodion, John Smyth and S. Gundersen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancer Chemotherapy and Pharmacology.

In The Last Decade

R Abele

23 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Abele Switzerland 10 175 154 52 48 40 23 369
K Clagett-Carr United States 7 164 0.9× 156 1.0× 48 0.9× 49 1.0× 32 0.8× 9 401
Sikic Bi United States 10 276 1.6× 282 1.8× 58 1.1× 30 0.6× 77 1.9× 13 547
Theresa Dunn Germany 10 195 1.1× 147 1.0× 96 1.8× 51 1.1× 95 2.4× 14 421
Todd D. Shenkenberg United States 7 123 0.7× 108 0.7× 32 0.6× 47 1.0× 18 0.5× 9 333
S P Khor United States 9 105 0.6× 254 1.6× 77 1.5× 34 0.7× 39 1.0× 10 422
H. Thomas United Kingdom 13 129 0.7× 158 1.0× 39 0.8× 42 0.9× 79 2.0× 32 427
Peter Nygren Sweden 11 141 0.8× 184 1.2× 54 1.0× 37 0.8× 28 0.7× 14 401
Joseph A. Sinkule United States 12 242 1.4× 276 1.8× 35 0.7× 48 1.0× 26 0.7× 14 489
DavidS. Alberts United States 9 135 0.8× 167 1.1× 71 1.4× 67 1.4× 123 3.1× 9 455
Masami Bungo Japan 7 264 1.5× 242 1.6× 42 0.8× 53 1.1× 27 0.7× 10 396

Countries citing papers authored by R Abele

Since Specialization
Citations

This map shows the geographic impact of R Abele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Abele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Abele more than expected).

Fields of papers citing papers by R Abele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Abele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Abele. The network helps show where R Abele may publish in the future.

Co-authorship network of co-authors of R Abele

This figure shows the co-authorship network connecting the top 25 collaborators of R Abele. A scholar is included among the top collaborators of R Abele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Abele. R Abele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anchisi, Sandro, et al.. (1998). Management of an isolated thymic mass after primary therapy for lymphoma. Annals of Oncology. 9(1). 95–100. 4 indexed citations
2.
Dulguerov, Pavel, Anne-Marie Kurt, Daniel Ruefenacht, et al.. (1998). Multiple myeloma presenting with external ear canal mass. The Journal of Laryngology & Otology. 112(5). 469–471. 8 indexed citations
3.
Weintraub, Jonathan, et al.. (1996). Concurrent interfollicular Hodgkin's disease and metastatic breast carcinoma in lymph nodes. Pathology International. 46(10). 787–790. 18 indexed citations
4.
Roth, Arnaud, R Abele, & Pierre Alberto. (1994). 13-<i>cis</i>-Retinoic Acid Plus Interferon-α: A Phase II Clinical Study in Squamous Cell Carcinoma of the Lung and the Head and Neck. Oncology. 51(1). 84–86. 8 indexed citations
5.
Glabbeke, M. van, J. Renard, Herbert M. Pinedo, et al.. (1988). Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG). European Journal of Cancer and Clinical Oncology. 24(2). 255–262. 39 indexed citations
6.
Abele, R, M. Clavel, P. Dodion, et al.. (1987). The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. European Journal of Cancer and Clinical Oncology. 23(12). 1921–1924. 92 indexed citations
7.
Abele, R, et al.. (1987). Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck. European Journal of Cancer and Clinical Oncology. 23(4). 387–389. 4 indexed citations
8.
Abele, R, et al.. (1986). Phase I study of cyclohexylamine and lysine salt of mafosfamide. Cancer Chemotherapy and Pharmacology. 16(2). 182–3. 5 indexed citations
9.
Abele, R, et al.. (1985). Induction chemotherapy with methotrexate, bleomycin and hydroxyurea with or without cisplatin in advanced squamous cell carcinoma of the head and neck: a study of the Swiss Group for Clinical Cancer Research (SAKK).. PubMed. 201. 169–75. 1 indexed citations
10.
Albers, Stefanie, et al.. (1984). Komplette parenterale Ernährung mit und ohne einem synthetischen Dipeptid (L-Alanyl-L-Glutamin) bei Ratten mit experimenteller Katabolie. Aktuelle Ernährungsmedizin. 9(4). 147–149. 4 indexed citations
11.
Abele, R, et al.. (1984). Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck. European Journal of Cancer and Clinical Oncology. 20(3). 333–336. 16 indexed citations
12.
Abele, R, P. Alberto, P Siegenthaler, et al.. (1983). Phase II study of doxifluridine in advanced colorectal adenocarcinoma.. Journal of Clinical Oncology. 1(12). 750–754. 34 indexed citations
13.
Abele, R, et al.. (1982). Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.. PubMed. 66(6). 1307–13. 18 indexed citations
14.
Rozencweig, Marcel, R Abele, Daniel D. Von Hoff, & Franco M. Muggia. (1981). Cisplatin: impact of a new anticancer agent on current therapeutic strategies.. PubMed. 1(4). 199–204. 16 indexed citations
15.
Piccart, Martine, et al.. (1981). Phase I clinical trial with ametantrone (NSC-287513). European Journal of Cancer and Clinical Oncology. 17(7). 775–779. 10 indexed citations
16.
Abele, R, et al.. (1981). Re-evaluation of the combination of CCNU, vincristine, and bleomycin in the treatment of malignant disseminated melanoma.. PubMed. 65(5-6). 505–6. 5 indexed citations
17.
Abele, R, Marcel Rozencweig, Jean‐Jacques Body, et al.. (1980). Carminomycin (NSC-180024): A phase I study. European Journal of Cancer (1965). 16(12). 1555–1559. 6 indexed citations
18.
Abele, R, et al.. (1979). Abdominal crisis due to metastasizing lung carcinoma to the small bowel.. PubMed. 22(4). 351–3. 15 indexed citations
19.
Abele, R, et al.. (1978). Carcinoma of the male breast and oestrogen metabolism. BMJ. 1(6128). 1697.4–1698. 9 indexed citations
20.
Abele, R, et al.. (1978). [Effect of guar on the gastrointestinal absorption of D-xylose: compartmental analysis on a computer].. PubMed. 53(9-10). 253–60. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026